
|Videos|March 1, 2018
Developing Combination Therapy Strategies for Ovarian Cancer
Author(s)Kathleen Moore, MD
Kathleen Moore, MD, associate director for clinical research at the Stephenson Oklahoma Cancer Center, discusses the development of combination therapy strategies for patients with ovarian cancer.
Advertisement
Kathleen Moore, MD, associate director for clinical research at the Stephenson Oklahoma Cancer Center, discusses the development of combination therapy strategies for patients with ovarian cancer.
Immunotherapy combinations are currently being tested in many clinical trials for patients with ovarian cancer. Moore says immune agents are being combined with antiangiogenic agents, PARP inhibitors, cytotoxic chemotherapy, as well as other immune agents.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
4
Early Relapse Guides Use of CAR T vs Other Options in LBCL
5








































